Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MEDLEY phase 2/3 trial of MEDI8897 versus palivizumab for RSV prevention in high-risk infants
MOH_2019-09-16_007405Phase 3Not yet recruiting
- Sponsor
- MedImmune
- Start
- Jul 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in respiratory syncytial virus disease (RSV) comparing MEDI8897 with palivizumab (2 arms). Planned start Jul 2019; status: not yet recruiting.
02
Drugs
nirsevimabpalivizumab
03
Conditions
respiratory syncytial virus disease (RSV)
Beyond the preview
Go deeper on MOH_2019-09-16_007405.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2019-09-16_007405.